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Diabetic retinopathy (DR) can be defined as damage to microvascular system in the retina due to
prolonged hyperglycaemia. The prevalence of DR in the Chennai Urban Rural Epidemiology
(CURES) Eye Study in south India was 17.6 per cent, significantly lower than age-matched western
counterparts. However, due to the large number of diabetic subjects, DR is likely to pose a public
health burden in India. CURES Eye study showed that the major systemic risk factors for onset
and progression of DR are duration of diabetes, degree of glycaemic control and hyperlipidaemia.
Hypertension did not play a major role in this cross-sectional analysis. The role of oxidative stress,
atherosclerotic end points and genetic factors in susceptibility to DR has been studied. It was
found that DR was associated with increased intima-media thickness and arterial stiffness in type
2 Indian diabetic subjects suggesting that common pathogenic mechanisms might predispose to
diabetic microangiopathy. Curcumin, an active ingredient of turmeric, has been shown to inhibit
proliferation of retinal endothelial cells in vivo. Visual disability from DR is largely preventable if
managed with timely intervention by laser. It has been clearly demonstrated that in type 2 south
Indian diabetic patients with proliferative DR who underwent Pan retinal photocoagulation, 73
per cent eyes with good visual acuity (6/9) at baseline maintained the same vision at 1 yr follow up.
There is evidence that DR begins to develop years before the clinical diagnosis of type 2 diabetes.
Our earlier study demonstrated that DR is present in 7 per cent of newly diagnosed subjects,
hence routine retinal screening for DR even at the time of diagnosis of type 2 diabetes may help in
optimized laser therapy. Annual retinal examination and early detection of DR can considerably
reduce the risk of visual loss in diabetic individuals.
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Diabetic retinopathy (DR) is a vascular disorder
affecting the microvasculature of the retina. It is
estimated that diabetes mellitus affects 4 per cent of
the world’s population, almost half of whom have
some degree of DR at any given time1. DR occurs
both in type 1 and type 2 diabetes mellitus and has
been shown that nearly all type 1 and 75 per cent of
type 2 diabetes will develop DR after 15 yr duration
of diabetes as shown in earlier epidemiological
studies2,3. In the western population, DR has been
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shown to be the cause of visual impairment in 86 per
cent of type 1 diabetic patients and in 33 per cent of
type 2 diabetic patients4.
In India with the epidemic increase in type 2
diabetes mellitus as reported by the World Health
Organization (WHO)5, diabetic retinopathy is fast
becoming an important cause of visual disability.
Visual disability from diabetes is a significant public
health problem; however this morbidity is largely
preventable and treatable. If managed with timely
intervention, the quality of life can be preserved. This
review aims at providing an overview of diabetic
retinopathy in the Indian scenario.
Classification and prevalence of diabetic
retinopathy
Diabetic retinopathy is primarily classified into
non proliferative DR (NPDR), formerly termed
simple, or background retinopathy, and proliferative
DR (PDR). Progression from mild, characterized by
increased vascular permeability, to moderate, and
then to severe NPDR characterized by vascular
closure and an increased risk for the development of
PDR2 distinguished by the growth of new blood
vessels on the retina and posterior surface of the
vitreous. Visual impairment in diabetic retinopathy
occurs due to diabetic macular edema (DME) and
PDR. DME is defined as retinal thickening/hard
exudates within 500 m of the centre of the macula
which is due to increased permeability of retinal
vessels leading to macular oedema and retinal
thickening. The other cause of visual impairment in
DR is PDR where there may be a sudden vitreous
haemorrhage from the unstable new vessels resulting
in total or partial visual loss or from pre-retinal
haemorrhage/fibrosis or traction at the macula.
The prevalence of DR varies in type 1 and type 2
diabetes. In type 1 diabetes in the EURODIAB IDDM
complications study, which included subjects
attending 31 European diabetes centres, the prevalence
of DR ranged between 25-60 per cent6. In India, there
is a paucity of data on the prevalence of DR in type 1
diabetes mellitus, as a registry for prevalence of type
1 diabetes is only recently being set up in the country.
An earlier study done in a clinic-based population
reported an overall prevalence of 14 per cent. NPDR
was observed in 6 per cent, while 4 per cent had
macular oedema and 4 per cent had PDR7. Asian
Young Diabetes Research (ASDIAB) Study, reported
the prevalence of DR in 724 young diabetic subjects
of age 12-40 yr with duration of diabetes < 12 months
in 7 centres of four Asian countries. It is interesting
to note that DR prevalence was least among Indians
(5.3%) as compared to other ethnic groups like Malays
(10%) and Chinese (15.1%)8. Higher levels of fasting
C-peptide and glucagon stimulated C-peptide among
the Indians in this study, may partly explain the lower
prevalence of DR in this group.
In a clinic population of a cohort of 6792 type
2 diabetic patients attending a diabetes centre at
Chennai in south India the prevalence of DR was
34.1 per cent. The retinal screening was done by a
combinat ion of  ophthalmoscopy and ret inal
photographs. The prevalence included 30.8 per
cent with NPDR, 3.4 per cent with PDR and 6.4
per cent had DME9. However, in the Chennai Urban
Rural  Epidemiology (CURES) Eye Study,  a
populat ion based s tudy which included a
representative sample of 26,001 individuals (urban
component), the overall prevalence of DR was 17.6
per cent among the 1715 diabetic subjects 10.
Among the known diabetic subjects, the overall
prevalence of DR was 20.8 per cent, while among
the newly detected diabetic subjects 5.1 per cent
had DR. Higher frequency of all the grades of
ret inopathy (overal l ,  NPDR and PDR) was
observed in known diabetic subjects compared to
newly detected cases (Fig. 1). Prevalence of DME
in the total diabetic population was 5.0 per cent
while among the known diabetic subjects it was
6.3 and 1.1 per cent among the newly diagnosed
diabetic subjects10. The CURES Eye study is the
first population-based study, which used four-field
stereo retinal photographs and Early Treatment
Diabetic Retinopathy Study (ETDRS) grading to
document DR in the Indian population11.
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Two other population-based studies conducted in
south India, reported overall prevalence of DR as 22.4
per cent12 and 26.8 per cent respectively; however they
were not based on retinal photography13. The
prevalence of DR in different socio-economic groups
was studied in the Chennai Urban Population Study
(CUPS), a population based study conducted in
Chennai, involving two residential areas representing
the lower and middle income group. The prevalence
of DR in the middle income group was 21.1 per cent
compared to 14.3 per cent in the low income group14.
It is noteworthy that the prevalence of diabetes was
higher in the middle income group (12.4%) compared
to lower socio-economic strata (6.5%), which is
contradictory to the western population studies where
diabetes is reported to be higher among the lower
economic strata15.
Lack of symptoms and the insidious onset of type
2 diabetes may result in development of DR at an
early stage16. Often DR is detected when type 2
diabetes is diagnosed. Rema et al17 in a study of 438
consecutive newly diagnosed type 2 diabetic patients
reported that 7.3 per cent already had diabetic
retinopathy. However, in the population based
CURES Eye study the prevalence of DR at onset of
type 2 diabetes was 6.7 per cent lower as expected
when a population based study is done18. These
figures are strikingly lower than those reported in
Europeans, where the prevalence of retinopathy at
diagnosis was reported to vary from 28 to 35 per
cent3,19. In studies conducted in USA and Australia,
the prevalence of retinopathy at the time of diagnosis
of type 2 diabetes varied from 10-21 per cent20-22.
The propensity to develop DR is lower in south
India compared to the other populations. Table I
provides the prevalence of DR in different
populations varying from 17.6 per cent in Chennai,
India, to 50.3 per cent in Wisconsin, US10,23-29. It has
been hypothesized that this may be due to the fact
that Indians develop type 2 diabetes at an earlier age,
but on matching for age the prevalence was still
significantly lower than their western counterparts
(19.2%). Inherent ethnic difference in the Indians in
relation to the susceptibility to DR may be one aspect
and another reason may be the type of diet which
although rich in carbohydrates includes more
vegetables, less fat and perhaps more antioxidants
and anti-inflammatory agents like curcumin.
Fig. 1. Prevalence of retinopathy - the Chennai Urban Rural Epidemiology Study. Source: Ref. 10.
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Molecular basis of diabetic retinopathy
The retinal changes in patients with diabetes
result from five fundamental processes: ( i) the
formation of retinal capillary microaneurysms, (ii)
the development  of  excessive vascular
permeability, (iii) vascular occlusion, (iv) the
prol iferat ion of  new blood vessels  and
accompanying fibrous tissue on the surface of the
retina and optic disk,  and (v) the contraction of
these f ibrovascular  prol i ferat ions and  the
vitreous30. The clinicopathological lesions of
diabetic retinopathy have been well classified.
Although a multitude of pathogenic mechanisms
have been proposed, the underlying dysfunctional
biochemical and molecular pathways that lead to
initiation and progression of DR still remains an
enigma.
Currently four major biochemical pathways have
been hypothesized to explain the mechanism of
diabetic eye diseases all starting initially from
hyperglycaemia induced vascular injury31. These
mainly include (i) enhanced glucose flux through the
polyol pathway, (ii) increased intracellular formation
of advanced glycation end-products (AGE), (iii)
activation of protein kinase C (PKC) isoforms, and
(iv) stimulation of the hexosamine pathway. Studies
have suggested that these mechanisms seem to reflect
a hyperglycaemia induced process initiated by
superoxide overproduction by mitochondrial electron
transport chain32.
Determinants of diabetic retinopathy
Epidemiological surveys have shown that various
risk factors known to be associated with diabetic
retinopathy, tend to accelerate its course and increase
its severity (Table II).
Systemic factors
Gender: Studies have shown varying results when
predicting gender as a risk factor for developing DR.
In the Joslin clinic patients, there appeared to be
excess females over males in the older-onset group,
however among those with PDR, males were equal
to females33. In the clinic cohort in Chennai DR
Table I. Studies on prevalence of diabetic retinopathy in different populations
Populations studied Place Year/period Participants with Prevalence of
diabetes (n) retinopathy (%)
Chennai Urban Rural Epidemiology Chennai, India 2003 -ongoing 1715 17.6
Study (CURES) - Eye Study-110
Los Angeles Latino Eye Study Los Angeles, USA 1999-2003 1217 46.9
(LALES)23
The Liverpool Diabetic Eye Liverpool, UK 1998 395 33.6
Study24
Barbados Eye Study25 Barbados, 1998 615 28.8
West Indies
Blue Mountains Eye Blue Mountain, 1992-1994 252 29.0
Study (BMES) 26 Australia
Taiwan27 Taiwan, Republic 1991 527 35.0
of China
Beaver Dam Eye Wisconsin, USA 1988-1990 410 35.1
Study (BDES) 28
Wisconsin Epidemiologic Study Southern Wisconsin, 1980-82 1313 50.3
of Diabetic Retinopathy29 USA
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appeared to be prevalent more in the males
compared to females (sex ratio 2 : 1)9. A similar
preponderance has been reported from the CURES
Eye study10, UKPDS study20 and the Hyderabad
study12.
Duration of disease: The duration of diabetes is
probably the strongest predictor for development and
progression of retinopathy. In the Wisconsin
Epidemiologic Study of Diabetic Retinopathy
(WESDR), the widest and most prolonged population
based ophthalmologic survey, reported that higher
prevalence of DR was associated with longer duration
of diabetes34. In persons with type 1 diabetes with
less than 5 yr of duration, the prevalence of
retinopathy was about 10 per cent, whereas it ranged
from 25 to 40 per cent in individuals with type 2
diabetes.
In India, virtually all studies have shown an
increased prevalence of DR as the duration of
diabetes increased10,12,14. In the study conducted by
Dandona et al12 in type 2 diabetes, it is reported that
87.5 per cent of those with >15 yr duration of diabetes
had DR compared with 18.9 per cent of those who
had <15 yr duration. In the CURES Eye study10,
41.8 per cent had DR after 15 yr of diabetes and
severity of DR proportionally increased with longer
duration of diabetes (Fig. 2). In addition, it has been
demonstrated that for every five year increase in
duration of diabetes, the risk for DR increased by
1.89 times10.
Glycaemic control: There is strong evidence to
suggest that the development and progression of DR
is influenced by the level of hyperglycaemia10,14,35.
The protective effect of glycaemic control on the
development and progression of DR has been
investigated in both type 1 (WESDR and Diabetes
Control and Complications Trial- DCCT) and type 2
diabetic patients (UKPDS)35-37.  In the 14 yr
progression of retinopathy study (WESDR), the
prevalence of retinopathy in type 1 diabetic subjects
was 12 per cent when glycated haemoglobin (HbA1c)
was <7 per cent as compared to 40.7 per cent when
HbA1c levels were >10 per cent and an increased
Fig. 2. Severity of retinopathy in relation to duration of diabetes. Source: Ref. 10.
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risk of PDR was associated with more severe baseline
retinopathy and higher HbA1c levels35. The DCCT
Research Group36 demonstrated that intensive therapy
reduced the mean risk of retinopathy by 76 per cent
as compared with conventional therapy in the
primary-prevention cohort. While in the secondary-
intervention cohort, intensive therapy reduced the risk
of eye complications by 54 per cent for the
development of DR, decreased progression of NPDR
to PDR or severe NPDR by 47 per cent and the need
for laser therapy by 56 per cent. Rema et al38 have
also shown that the visual outcome of laser
photocoagulation for eyes with PDR was also
dependent on the degree of glycaemic control.
In the CURES Eye Study, a linear trend in the
prevalence of retinopathy with increase in quartiles
of HbA1c (trend Chi square: 51.6, P<0.001) from
8.1 per cent (HbA1c level < 6.9 %) to 31.7 per cent
(HbA1c level >10.3%) was observed. For every 2
per cent elevation of HbA1c, the risk for DR
increased by a factor of 1.710. In the UKPDS37, the
risk reduction in eye complications for every 1 per
cent decrease in HbA1c was 19 per cent. Thus it is
observed that long term glycemic control plays an
important role in delaying the onset and lowing down
the progression of DR.
Hypertension: Increased blood pressure has been
hypothesized, through the effects of increased sheer
stress of blood flow, to damage the retinal capillary
endothelial cells in eyes of people with diabetes39.
The possible mechanisms by which hypertension may
affect DR are haemodynamic (impaired auto
regulation and hyperperfusion) and through VEGF
(vascular endothelial growth factor). This hypothesis
has been supported by observations from clinical
studies which showed an association between
hypertension and the presence and severity of
retinopathy in people with diabetes38,40.
The UKPDS showed that the incidence of
retinopathy was associated with systolic blood
pressure41, while in the WESDR, diastolic blood
pressure was a significant predictor of progression
of diabetic retinopathy to PDR over 14 yr of follow
up in patients type 1 diabetes35. In the Indian context,
hypertension was not a significant confounding factor
in the CURES Eye study, however uncontrolled
hypertension did influence the progression of DR10.
Renal disease: A link between renal and retinal
angiopathy in diabetes has been long recognized, an
effect that may be mediated through an increase in
blood pressure, fibrinogen levels and lipoproteins42.
Cross-sectional43 and longitudinal studies44,45 report
a relationship between microalbuminuria, proteinuria
and retinopathy. Proteinuria was present in 29.2 per
cent of the subjects with DR in the CURES Eye
study10, while studies from north India46,47 have
Table III. Potential molecules for the management of diabetic
retinopathy
Agent Molecules tried
Anti-platelet or anticoagulant Aspirin88
agents
Anti-platelet agents Ticlopidine89
Aldose reductase inhibitors Ponalrestat90
Tolrestat91
Growth hormone suppressors Octreotide92
Anti angiogenic agent Curcumin87
Angiotension-converting Candesartan cilexetil93
enzyme inhibitors Perinodopril94
PKCb inhibitors Ruboxistaurin
 (LY333531)95
PKC412 96
PKC, protein kinase  C
Table II. Risk factors associated with the development of
diabetic retinopathy
Systemic factors Ocular factors
Gender Posterior vitreous detachment
Duration of diabetes
Glycaemic control Old chorioretinopathy
Hypertension Cataract surgery
Renal disease
Elevated serum lipids
Pregnancy
Alcohol
Anaemia
Obesity
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suggested a correlation between DR and
microalbuminuria. Mohan et al48 reported that the
prevalence of proliferative retinopathy  was
significantly higher in type 2 south Indian diabetic
patients with macroproteinuria (35%) compared with
those with microproteinuria (4%). A recent study
done by Klein et al49 demonstrated a significant
association between DR and preclinical morphologic
changes of diabetic nephropathy in type 1 diabetic
patients.
Elevated serum lipids: Individuals with elevated total
serum cholesterol, low-density lipoprotein (LDL)
cholesterol or triglyceride levels are more likely to
have or develop retinal hard exudates, which can be
associated with risk of vision loss, independent of
the extent of macular oedema50. Several investigators
have reported on the association of lipids with DR,
but the results have not been consistent. The ETDRS51
and the WESDR group52 found a statistically
significant association between elevated serum total
cholesterol and LDL cholesterol and the severity of
retinal hard exudation in patients with DR.
Rema et al53 in an earlier study showed an
association of DME in type 2 diabetic subjects with
increased LDL levels. Other studies have
demonstrated that decreasing dietary polyunsaturated
fats may have an association with shrinkage of
exudates and a treatment apt to lower plasma lipid
levels reduced the risk size of perimacular hard
exudates. It has also been shown that in type 2
diabetic subjects there was an increase in the lipid
peroxidation in plasma and this is accentuated in
patients with diabetic complications54. A recent paper
from the CURES eye study55 showed an association
of DR with total cholesterol and serum triglycerides.
This association was maintained even after adjusting
for age, as age by itself is a significant risk factor for
hyperlipidaemia. The other significant finding in type
2 diabetes was that DME also showed a strong
correlation with high LDL levels in the study.
Pregnancy: It is recognized that DR can progress
rapidly during pregnancy due to hormonal changes.
The progression is usually transient and the long term
risk of progression of DR does not appear to be
increased by pregnancy56. The factors associated with
progression of DR include the pregnant state itself,
duration of diabetes, amount of retinopathy at
conception, blood glucose control, and the presence
of coexisting vascular disease57. There is a paucity
of published data on the role of pregnancy as a risk
factor for DR in Indians. Studies conducted in
western population report that progression of all
stages of DR can occur in pregnant women with
uncontrolled diabetes mellitus. Both the DCCT56 and
the Diabetes in Early Pregnancy Study58 reported that
women with the poorest glycaemic control at baseline
in the 1st trimester were at increased risk of DR
progression.
Alcohol: A few studies have examined the effect of
alcohol consumption on DR. Young et al59 reported
heavy alcohol consumption to be a risk factor for
development of DR in patients without retinopathy
at baseline. The Casteldaccia Eye Study60
demonstrated that duration of alcohol intake was
associated with DR. In contrast, WESDR showed no
significant association with incidence or progression
of retinopathy61.
Anaemia: Anaemia is considered another risk factor,
perhaps because of smaller amounts of oxygen for
the retinal tissue62. Singh et al63 reported spontaneous
closure of the microaneurysms on correction of
anaemia and metabolic control in type 1 diabetic
patient with coexisting nutritional anaemia. In the
ETDRS, low haematocrit was an independent risk
factor for development of high risk PDR and visual
impairment64. A Finnish study65 showed that the odds
ratio of having any retinopathy was two-fold among
subjects with a haemoglobin level of less than 12 g/
dl, as compared with those having a higher
haemoglobin level, even after controlling for serum
creatinine levels, proteinuria, and other prognostic
factors associated with diabetes. In addition, DR
patients with low haemoglobin levels, had over five-
fold increased risk of severe retinopathy compared
to those with higher haemoglobin levels.
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Obesity: Recent studies have shown that DR may not
only be associated with glycaemic control and blood
pressure, but also to body mass index (BMI) in
patients with type 2 diabetes66,67. Perhaps variation
in ethinicity may explain the fact that BMI did not
manifest as a risk factor for DR in the CURES Eye
study. On the contrary subjects with type 2 diabetes
and PDR had a lower BMI10. Zhang et al68 in the
diabetes control and complications trial (DCCT)
observed that besides diabetes duration and metabolic
control, BMI had a significant predictive value in
developing retinopathy.
Ocular factors
Posterior vitreous detachment (PVD) is a
phenomenon, which occurs due to degenerative
changes in the vitreous and significantly more
common in diabetic subjects. It has been shown that
a complete PVD may prevent the development of
PDR because the hyaloid is needed as a scaffold for
retinal neovascularization69. An attached posterior
hyaloid has also been associated with an increased
risk for DME70.
High myopia with choroidal degeneration and
extensive old chorioretinopathy protect against DR
and are believed to act in the same manner as pan
retinal photocoagulation by reducing the metabolic
needs of the retina71.
Removal of a cataract may aggravate both
existing DME and NPDR and may hasten the onset
of rubeosis72. In the Palakkad Eye Disease Survey,
which looked at visual impairment and blindness in
the population reported that cataract (27.8%) was one
of the major causes for visual disability among
subjects with diabetes13. In a retrospective analysis
done in 223 eyes of 184 type 2 diabetic subjects who
underwent cataract surgery, it has been reported that
44 per cent had progression of DR after cataract
surgery and 8.0 per cent developed DR for the first
time, this was mainly in patients who underwent extra
capsular cataract extraction with intra ocular lens
(IOL) implantation73 [Presented at the Vitreo-Retinal
Society of India. Annual Conference, Goa, 2002].
This emphasizes the need of routine retinal
documentation and detecting DR before cataract
extraction.
Other factors
In addition to systemic and ocular factors, recent
studies in western population have shown that DR is
associated with atherosclerotic end points73,74. The
CURES study, which assessed the association of
intima-media thickness (IMT) and arterial stiffness
(AI) with diabetic retinopathy in 590 south Indian
population demonstrated that IMT and AI showed a
significant association with diabetic retinopathy, even
after adjusting for age, duration of diabetes, HbA1c,
serum cholesterol, serum triglycerides, and
microalbuminuria75. This association suggests that
common pathogenic mechanisms might predispose
to diabetic micro- and macroangiopathy.
The role of oxidant stress in the causation of DR
is increasingly being recognized76,77. Very recently
it has also been shown that hypoglutathionaemia and
increased oxidative stress appear to be early
biochemical aberrations in diabetes, and through
protein alterations, oxidative stress and redox
modifications may contribute to pathogenesis of
diabetic microangiopathy78. Increased erythrocyte
glutathionylated Hb (HbSSG) levels with decreased
glutathione (GSH) was shown to be associated with
DR indicating that the increased oxidative stress may
be one of the implicating factors in the pathogenesis
of DR79.
The role of genetic factors in susceptibility to
retinopathy has been studied recently as some
patients develop DR despite good control and others
escape retinopathy despite poor control80,81. In a study
conducted in 322 type 2 diabetic families, Rema
et al80 reported that there was a familial clustering
of diabetic retinopathy among siblings of diabetic
probands with and without DR. The odds ratio was
3.5 suggesting that siblings of the probands with DR
had 3.5 times higher risk of developing retinopathy.
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It has also been demonstrated that in Mexican-
American type 2 diabetic siblings of probands with
DR, severity of DR aggregates in families rather than
the presence of DR itself81.
Screening and management
As individuals with sight-threatening retinopathy
(PDR and DME) may not have symptoms, life-long
evaluation for retinopathy by retinal screening of
diabetic individuals is a valuable and necessary
strategy. Screening strategies depend on the rate of
appearance and progression of diabetic retinopathy and
on the risk factors that alter these rates. The retina
may be examined by ophthalmoscopy and slit lamp
biomicroscopy using 78 D lens, or by using retinal
photography82. It has been shown that seven-standard
field stereoscopic 30° fundus photography is the gold
standard for assessing DR, however digital colour
photography have now replaced this cumbersome
mode of screening. Recently several new, noninvasive
techniques promise to improve diagnostic sensitivity,
one such technique is the optical coherence
tomography (OCT). This method co-relates well with
fundus fluorescein angiography (FFA)83.
Laser photocoagulation and vitrectomy have
improved the quality of life for patients with DR and
prevented debilitating visual loss84,85. In a study
conducted in 261 eyes of 160 type 2 diabetic subjects
with PDR who underwent pan retinal photocoagulation
(PRP), 73 per cent eyes maintained >6/9 at 1 yr follow
up38. However, laser photocoagulation and vitrectomy
are indicated only when DR has progressed to a
measurably advanced stage in which some visual loss
has already occurred. Because of these limitations of
current management strategies, new pharmacological
therapies are being developed; targeting the
fundamental pathogenic mechanisms that initiate or
sustain the progression of DR. Currently recalcitrant
DME has been treated with moderate success by intra-
vitreal injections of steroids86.
Various antiproliferative agents which have been
tried in anti-cancer therapy, are being tried in PDR.
Curcumin (diferuloylmethane) an active ingredient
of turmeric, has been tried successfully as an
antiproliferative agent. The effect of curcumin on
human retinal endothelial cells (HERCs) exposed to
high glucose has been published recently87. It was
demonstrated that curcumin inhibited the
proliferation of HERCs, in a dose-dependent manner
by inducing cell death in HRECs cultured with high
glucose conditions. The authors also suggest that
curcumin reduces proliferation of HRECs by
decreasing VEGF expression/release and VEGF
mediated PKC bII translocation. Table III
summarizes various molecules tried in DR
management87-96.
Conclusions
As new therapies for DR and its associated
complications emerge, the need to collect and
monitor new epidemiological data becomes
increasingly important to be able to evaluate the
impact and effectiveness of these therapies. Although
urban Indian population based studies suggest that
the prevalence of DR is lower compared to other
ethnic groups, given the large number of diabetic
subjects in India (31.7 million), even with the lower
prevalence rates (17.6%), this would translate to over
5.6 million subjects with DR. This underscores the
need for routine retinal screening of diabetic
individuals annually to detect DR and prevent visual
impairment. In addition, optimized control of
systemic considerations, which affect onset and/or
progression of DR, through an intensive, multi-
disciplinary, healthcare team-based approach, can
markedly reduce impairment of vision due to DR.
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